Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KITE-753
- Development stage
- Phase 3
- Lead developer
- Kite Pharma
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Gene Addition/Replacement → Gene Therapies, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Covalent Small Molecules → Small Molecules, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KITE-753 is an autologous chimeric antigen receptor T (CAR-T) cell therapy developed for the treatment of B-cell malignancies, specifically relapsed and/or refractory large B-cell lymphoma. The therapy uses a rapid manufacturing process to engineer a patient’s own T cells with a bicistronic lentiviral vector, resulting in the expression of both anti-CD19 and anti-CD20 CARs on the cell surface. This dual-targeting approach enables recognition and elimination of tumor cells expressing either CD19 or CD20 antigens. KITE-753 demonstrates enhanced potency, proliferation, IL-2 production, and antitumor efficacy compared to traditional CAR-T products. It is currently in Phase 1 clinical trials[1][2][3][5][6][8].
- Other names
- CD19/CD20 bicistronic
02
Targets
Beyond the preview
Go deeper on KITE-753.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KITE-753.